Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitura HealthASX:VIT -6.67% 3-1 Month Momentum % is -38.89% as of Jul. 27, 2026. The stock has 8 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Vitura Health ranks worse than 94.24% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-27), Vitura Health's 3-1 Month Momentum % is -38.89%.
The industry rank for Vitura Health's 3-1 Month Momentum % or its related term are showing as below:
ASX:VIT's 3-1 Month Momentum % is ranked worse than 94.24% of 1024
companies
in the Drug Manufacturers industry
Industry Median: -8.205
vs ASX:VIT: -38.89
Vitura Health (ASX:VIT) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vitura Health 3-1 Month Momentum % Related Terms
ASX:VIT vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vitura Health's 3-1 Month Momentum % falls into.
Vitura Health (ASX:VIT) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a 3-1 Month Momentum % of -38.89% as of Jul. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vitura Health and its competitors. According to the industry distribution chart, Vitura Health ranks #965 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 94.2%.
Is Vitura Health's 3-1 Month Momentum % too high?
Vitura Health's current 3-1 Month Momentum % is -38.89%. Based on the distribution chart, Vitura Health ranks #965 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Vitura Health's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #965 out of 1024 companies for 3-1 Month Momentum %. This places Vitura Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vitura Health and its competitors. Vitura Health's current 3-1 Month Momentum % is -38.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 72% below its estimated fair value. The current 3-1 Month Momentum % is -38.89%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current 3-1 Month Momentum % is -38.89% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 
